deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT00877500

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Bilateral Breast Carcinoma HER2/Neu Negative Invasive Breast Carcinoma
Interventions Best Practice Ixabepilone
Updated 19 times since 2017 Last updated: Nov 6, 2025 Started: Mar 30, 2009 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bilateral Breast Carcinoma and HER2/Neu Negative and is currently ongoing. M.D. Anderson Cancer Center leads this study, which shows 19 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Sep 2017 · 8 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2022 · 14 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Jun 2025 · 5 months · monthly snapshot~Jun 2025 – ~Dec 2025 · 6 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Feb 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  10. Nov 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  11. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  13. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  14. Jan 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations